Company Overview and News
New Delhi: The Delhi high court on Thursday directed the National Highway Authority of India (NHAI) to pay the remaining 25% of multiple arbitral awards—amounting more than Rs2,000 crore—to Hindustan Construction Co Ltd (HCC) within two weeks.
Auditor of the company’s unit Lavasa Corp says it has “significant doubts about the company’s ability to continue as a going concern”
The first quarter of calendar year 2018 has not been too good for Indian investors, with benchmark indices reversing sharply in February.
Lavasa Corporation, a subsidiary of Hindustan Construction Company (HCC), in a reply to BSE query, has clarified that the media report about the company filing for bankruptcy is 'misleading' and 'without any basis'.
3:30 pm Market Update: Benchmark indices closed lower on Thursday after the US Federal Reserve's interest rate hike.
Shares of Hindustan Construction Company fell 15.6 percent intraday on Thursday, despite a clarification from the company on a report that its subsidiary Lavasa Corporation is planning to file for bankruptcy.
2:58 pm Land Allotment: Emami Paper Mills said the company has been allotted 4,00,387.05 square meters of land in Sayakha Industrial Estate, District Bharuch, Gujarat, by Gujarat Industrial Development Corporation (GIDC) for greenfield expansion project for manufacturing of paper boards.
Hindustan Construction Company share price fell 15.6 percent intraday on Thursday despite clarification from the company on Lavasa bankruptcy report.
12:46 pm Market Update: The market was rangebound after investors digested Fed rate hike, with the Nifty hovering around 10,150 levels.
12:05 pm Market Update: Benchmark indices erased gains in noon, with the Sensex falling 20.11 points to 33,116.07 and the Nifty declining 6.40 points to 10,148.90.
New Delhi: The initial public offer (IPO) of Tara Chand Logistic Solutions, through which the firm aims to raise over Rs20 crore, will open on 13 March.
The initial public offer of Tara Chand Logistic Solutions, through which the firm aims to raise over ₹ 20 crore, will open on March 13.
Shares of construction companies gained 1-4 percent intraday Thursday after Finance Minister announced that the highway construction will exceed 9,000 km by end of FY18.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Hindustan Construction Company (HCC) today said its joint venture firm has bagged a contract worth Rs 484 crore from the Maharashtra Metro Rail Corporation for the Pune metro project. “Hindustan Construction Company, a lead partner in the joint venture with AL FARA’A, has been awarded a Rs 484-crore contract by the Maharashtra Metro Rail Corporation Ltd for the Pune metro rail project,” HCC said in a BSE filing.
7m - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...